Complete and durable responses in Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab and Dexamethasone.

CONCLUSIONS:   EBV+ PCNS-PTLD expressed lytic kinases and therapy with AZT, GCV, rituximab and dexamethasone provided durable responses. Induction of the lytic protein expression and increased cellular sensitivity to antiviral therapy after transfection with viral kinase cDNA provides a mechanistic rationale for our approach.
PMID: 29632007 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 9, 2018 Category: Cancer & Oncology Authors: Dugan JP, Haverkos BM, Villagomez L, Martin L, Lustberg ME, Patton JT, Martin M, Huang Y, Nuovo G, Yan F, Cavaliere R, Fingeroth JD, Kenney SC, Ambinder RF, Lozanski G, Porcu P, Caligiuri MA, Baiocchi RA Tags: Clin Cancer Res Source Type: research